INOCARD
InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure, targeting the calcium-binding protein S100A1.
INOCARD
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2013-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Status:
Active
Similar Organizations
Cardiola
Cardiola is a biotechnology company developing therapeutic systems for the treatment of chronic heart failure.
NeuroTargets
NeuroTargets is a biotechnology company that researches and develops drugs for the treatment of neurological diseases.
More informations about "InoCard"
InoCard Company Profile 2025: Valuation, Investors, Acquisition
InoCard was founded in 2014. Where is InoCard headquartered? InoCard is headquartered in Heidelberg, Germany. What industry is InoCard in? InoCard’s primary industry is …See details»
uniQure acquires the gene therapy start-up InoCard
Aug 20, 2014 InoCard founders Prof. Patrick Most and Prof. Hugo Katus will join uniQure as Managing Director of uniQure in Germany and Chairman of the …See details»
uniQure Acquires Cardiology Gene Therapy Company InoCard
Aug 11, 2014 Confirmation Code: 5826325. Local - London, United Kingdom: +44(0)20 3427 1917. Local - New York, United States of America: +1212 444 0896. Local - Berlin, Germany: …See details»
uniQure Acquires InoCard, Gene Therapy For CHF - Clinical Leader
Aug 14, 2014 InoCard is an early stage biotech company that specializes in developing gene therapy approaches for the treatment of cardiac diseases. The company’s lead program …See details»
InoCard - MCEI
Inocard GmbH is a Heidelberg-based Medtech venture which has developed a gene therapy for heart insufficiency. The founders Prof. Dr. Hugo Katus, medical director of the Heidelberg …See details»
InoCard GmbH Company Profile, Financial and Strategic SWOT
InoCard GmbH is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure, targeting the calcium-binding protein …See details»
InoCard - Ownership and Business Overview - Mergr
InoCard was founded in 2013. Life Science M&A Summary in 2014. Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2014. The largest life science acquisition …See details»
UniQure acquires InoCard - 2014-08-12 - Crunchbase
Acquired Organization: InoCard InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure. Acquiring …See details»
uniQure acquires cardiology gene therapy company InoCard
Aug 13, 2014 uniQure, an Amsterdam, Netherlands-based provider of human gene therapy, has acquired InoCard, a Germany-based early-stage biotechnology company focused on the …See details»
Volunteer Photo ID Badges for Nonprofits - InstantCard
ALL TEMPLATES ARE DESIGNED FOR FREE. Example ID Design For Nonprofit Organizations. Our professional designers will create a custom ID template based on your specifications. We do not use generic badge …See details»
Uniqure übernimmt InoCard - GoingPublic.de
Aug 18, 2014 Most, der InoCard bei besagtem Wettbewerb erfolgreich vertrat, künftig als Managing Director für Uniqure tätig sein. Auch Christian Tidona, Geschäftsführer des BioRN …See details»
InoCard - Crunchbase
InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure. Search Crunchbase. Start Free Trial . Chrome …See details»
uniQure acquires cardiology gene therapy firm InoCard
Aug 12, 2014 InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease …See details»
uniQure Acquires Cardiology Gene Therapy Company InoCard
Aug 12, 2014 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology …See details»
Uniqure adds heart failure gene therapy with Inocard acquisition
Gene therapy pioneer Uniqure NV is moving into the field of complex disease, by purchasing Inocard GmbH, an early stage German start-up focused on congestive heart failure (CHF), in a …See details»
Non-Profit ID Card Templates - AlphaCard
Below you will find a range of card templates which you can download and customize for your organization. You can easily change, remove, or add text fields and images, and change …See details»
uniQure Acquires Cardiology Gene Therapy Company InoCard
InoCard founders Prof. Patrick Most and Prof. Hugo Katus will join uniQure as Managing Director of uniQure in Germany and Chairman of the Scientific Advisory Board, for Cardiovascular …See details»
Israel News: Updates on Israeli Politics, Security & Diplomacy | The ...
The Jerusalem Post Customer Service Center can be contacted with any questions or requests: Telephone: *2421 * Extension 4 Jerusalem Post or 03-7619056 Fax: 03-5613699 E-mail: …See details»
10 Components Of An Excellent Employee Id Card - IDville
1. ORGANIZATION LOGO. Add a visual security element to ID cards by incorporating your organization's logo. Be sure your ID card design is consistent with the current marketing style …See details»
OpenAI Non-Announcement: Requiring identity card verification …
Apr 14, 2025 Only one verify per 90 days per ID, regardless of organization count you administer or that are a business, LLC, or corporation with rotating principals. Yes, it is now live and likely …See details»